- cafead Jul 02, 2024 at 11:42: AM
via In a major win for Johnson & Johnson and Legend Biotech, their star CAR-T therapy Carvykti showed it can prolong the lives of patients with previously treated multiple myeloma.
J&J and Legend announced the “statistically significant and clinically meaningful” overall survival win Tuesday from the phase 3 CARTITUDE-4 trial, which compared Carvykti with standard combination therapies in myeloma patients who had tried one to three prior lines of therapy.
article source
J&J and Legend announced the “statistically significant and clinically meaningful” overall survival win Tuesday from the phase 3 CARTITUDE-4 trial, which compared Carvykti with standard combination therapies in myeloma patients who had tried one to three prior lines of therapy.
article source